Mod GRF, GHRP-2 10mg (Blend)

68.00 USD

Availability: In stock

FREE Shipping for orders over $200 (USA Only)

$15.00 Flat Rate Shipping Worldwide (Most Countries) 

*Includes one 30mL Bacteriostatic Water with orders over $300.00

$68.00
  • Buy 5 for $65.00 each and save 5%
  • Buy 10 for $63.00 each and save 8%
Modified GRF 5mg, GHRP-2 5mg (10mg Total Blend)

Mod GRF, GHRP-2 10mg (Blend)

Product Usage: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

Growth hormone secretagogue receptor (GHSR) agonists like GHRP-2 are well known for their ability to produce large spikes in GH levels. These spikes, while providing a number of interesting and important benefits in animal models, are also short-lived because the half-life of most GHSR agonists is relatively short. To achieve long-term GH level increases, it is possible to use a GHRH analogue like modified GRF. This provides a long-term increase in both basal and peak GH levels, but nowhere near the kind of GH spike that a GHSR agonists provides. In addition, animal models show that GHRH analogues are susceptible to somatostatin interference, which can offset increases in GH levels.

To get the best of both worlds, research into combining GHSR agonists and GHRH analogues is being undertaken. One particularly researched combination is modified GRF with GHRP-2[1]. The synergy provides increased basal and peak levels of GH as well as measured spikes that boost the benefits of both peptides in ways that simply increasing one or the other cannot.

The net result of combining these peptides is improved GH release and substantial shifts in metabolism away from fat deposition. Lean body mass is increased substantially, insulin levels fall, and blood sugar becomes more regulated[2]–[4]. There is even evidence to show that both peptides, but particularly ipamorelin, can help to improve bone mineral density and bone health[5], [6].

About The Author

Research by L. Edmiston, M.D. for Peptide Sciences. L. Edmiston holds an M.D. from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Resources

  • [1] M. Waelbroeck, P. Robberecht, D. H. Coy, J.-C. Camus, P. D. Neef, and J. Christophe, “Interaction of Growth Hormone-Releasing Factor (GRF) and 14 GRF Analogs with Vasoactive Intestinal Peptide (VIP) Receptors of Rat Pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(l-29)-NH2 as a VIP Antagonist,” Endocrinology, vol. 116, no. 6, pp. 2643–2649, Jun. 1985. [PubMed]
  • [2] A. V. Schally, X. Zhang, R. Cai, J. M. Hare, R. Granata, and M. Bartoli, “Actions and potential therapeutic applications of growth hormone-releasing hormone agonists,” Endocrinology. [PubMed]
  • [3] E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]
  • [4] D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]
  • [5] N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]
  • [6] J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]